Global Blood Therapeutics Inc (NASDAQ:GBT) – Investment analysts at Wedbush decreased their Q2 2019 earnings per share (EPS) estimates for Global Blood Therapeutics in a research report issued on Monday, May 13th. Wedbush analyst L. Moussatos now anticipates that the company will post earnings per share of ($0.95) for the quarter, down from their prior forecast of ($0.87). Wedbush currently has a “Buy” rating and a $95.00 price target on the stock. Wedbush also issued estimates for Global Blood Therapeutics’ Q3 2019 earnings at ($1.00) EPS, Q4 2019 earnings at ($0.99) EPS, FY2019 earnings at ($3.79) EPS, Q1 2020 earnings at ($0.99) EPS, Q2 2020 earnings at ($0.99) EPS, Q3 2020 earnings at ($0.81) EPS, Q4 2020 earnings at ($0.63) EPS, FY2020 earnings at ($3.43) EPS, FY2021 earnings at $0.02 EPS, FY2022 earnings at $3.82 EPS and FY2023 earnings at $9.21 EPS.
A number of other brokerages also recently weighed in on GBT. BidaskClub upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, May 10th. ValuEngine upgraded Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Wells Fargo & Co boosted their price target on Global Blood Therapeutics from $85.00 to $96.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. William Blair restated a “buy” rating on shares of Global Blood Therapeutics in a report on Wednesday, January 30th. Finally, Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research report on Monday, February 4th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $88.38.
Global Blood Therapeutics stock opened at $60.79 on Thursday. The company has a market cap of $3.27 billion, a P/E ratio of -17.83 and a beta of 2.10. The company has a current ratio of 14.51, a quick ratio of 14.38 and a debt-to-equity ratio of 0.04. Global Blood Therapeutics has a one year low of $30.15 and a one year high of $62.50.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.07.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY increased its holdings in Global Blood Therapeutics by 3.4% in the first quarter. Metropolitan Life Insurance Co NY now owns 16,873 shares of the company’s stock valued at $893,000 after purchasing an additional 562 shares during the period. FMR LLC boosted its position in shares of Global Blood Therapeutics by 1.1% during the 1st quarter. FMR LLC now owns 8,417,709 shares of the company’s stock worth $445,549,000 after purchasing an additional 88,310 shares in the last quarter. Kore Private Wealth LLC bought a new position in Global Blood Therapeutics in the 1st quarter valued at about $53,000. Jane Street Group LLC lifted its position in Global Blood Therapeutics by 21.4% in the 1st quarter. Jane Street Group LLC now owns 11,969 shares of the company’s stock valued at $634,000 after acquiring an additional 2,111 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its position in Global Blood Therapeutics by 1.8% in the 1st quarter. Perceptive Advisors LLC now owns 5,525,726 shares of the company’s stock valued at $292,476,000 after acquiring an additional 100,000 shares in the last quarter.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.